The Evidence Pack: How Accelerated TMS and the SAINT Protocol Are Rewriting Treatment-Resistant Depression

For decades, psychiatry has relied primarily on systemic chemical interventions—antidepressants that flood the brain to alter neurotransmitter levels. But for the 30% to 40% of patients with major depressive disorder who do not respond to these medications, the standard pharmacological toolkit offers diminishing returns.[3][6]

This clinical bottleneck has driven the rise of "circuit-based psychiatry," which treats depression not as a chemical imbalance, but as an electrical routing problem. Transcranial magnetic stimulation (TMS), which uses targeted magnetic pulses to reset misfiring brain circuits, has been FDA-cleared and utilized since 2008.[2][4]

However, traditional TMS requires a grueling schedule: 36 daily sessions stretched over six to eight weeks. This time commitment costs patients their mornings, their commutes, and sometimes their jobs, placing the treatment out of reach for many who need it most.[4]

Now, a next-generation approach known as accelerated TMS is rewriting the timeline and efficacy of depression care. The most prominent of these, the SAINT protocol (Stanford Accelerated Intelligent Neuromodulation Therapy), compresses a full six-week course of brain stimulation into just five days.[2][6]

The FDA-cleared SAINT protocol delivers 10 stimulation sessions per day. Each session lasts roughly 10 minutes, followed by a 50-minute resting period, repeated over five consecutive days to leverage the brain's neuroplasticity.[2][3]

But speed is only half of the breakthrough. The defining innovation of SAINT is its use of functional magnetic resonance imaging (fMRI) to personalize the treatment to the patient's unique neuroanatomy.[1][3]

In traditional TMS, clinicians use generalized scalp measurements to guess the location of the dorsolateral prefrontal cortex—the brain's mood-regulating doorway. Because human brain anatomy varies significantly, this "one-size-fits-all" targeting often misses the optimal neural circuit.[1][2]

SAINT uses an fMRI scan to map a patient's unique brain connectivity before treatment begins. By analyzing how different brain regions synchronize at rest, the system identifies the exact millimeter-level target that connects to the subgenual cingulate, a deep-brain structure that is hyperactive in depression.[1][3]

The clinical results of this precision targeting have been unprecedented in psychiatric care. In double-blind, randomized trials, nearly 80% of participants receiving the SAINT protocol achieved full remission from severe, treatment-resistant depression within five days.[2][3]

For context, patients in these trials had suffered from severe depression for years and failed multiple medication trials. The average time to remission under the accelerated fMRI-guided protocol was just 2.6 days.[3][6]

New data published in June 2026 in JAMA Psychiatry by investigators at Mass General Brigham further validates the fMRI approach. In a randomized trial comparing fMRI-guided accelerated TMS to conventional scalp-based targeting, the precision group achieved an 80% response rate, compared to 60% for the scalp-based group.[1]

"Because SAINT requires neuroimaging, this clearance marks the first official involvement of radiology in mental illness care," noted Dr. Nolan Williams, director of the Stanford Brain Stimulation Lab, highlighting the shift toward objective, biomarker-driven psychiatry.[3]

Other accelerated protocols are also showing promise. A 2026 retrospective analysis found that a "5x5" regimen—five sessions a day for five days—produced efficacy comparable to the conventional six-week course, even without fMRI guidance, offering a middle ground for clinics without imaging access.[4][5]

Despite the clinical triumphs, significant access barriers remain. While the hardware is FDA-cleared, insurance reimbursement has lagged behind the science. As of 2026, Medicare and many private insurers only reimburse up to two TMS sessions per day.[4]

This coverage gap means that while the five-day, 50-session protocol is highly effective, it often remains an out-of-pocket expense, creating a two-tiered system where only wealthy patients can access rapid remission.[4][6]

Nevertheless, the transition from chemical psychiatry to precision neural-circuit modulation is accelerating. By proving that severe depression can be reversed in days rather than months, accelerated TMS has fundamentally changed the expectations for psychiatric recovery.[2][6]